Log In
BCIQ
Print this Print this
 

Glufosfamide

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionGlucose analog conjugated to an alkylating agent
Molecular Target DNA
Mechanism of ActionAlkylating agent
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPancreatic cancer
Indication DetailsSecond-line treatment of relapsed or refractory pancreatic cancer; Treat advanced pancreatic cancer as first-line therapy; Treat pancreatic cancer; Treat refractory metastatic pancreatic cancer; Treat unresectable locally advanced or metastatic pancreatic adenocarcinoma
Regulatory Designation U.S. - Fast Track (Treat unresectable locally advanced or metastatic pancreatic adenocarcinoma);
U.S. - Orphan Drug (Treat pancreatic cancer);
U.S. - Special Protocol Assessment (Treat pancreatic cancer);
EU - Orphan Drug (Treat pancreatic cancer)
PartnerEleison Pharmaceuticals Inc.;
MediBIC Group;
Threshold Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/31/2011

Undisclosed

Undisclosed

Undisclosed

10/26/2009

0

0

0

Get a free BioCentury trial today